

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for TL314231V

CACNG5 Human shRNA Lentiviral Particle (Locus ID 27091)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	CACNG5 Human shRNA Lentiviral Particle (Locus ID 27091)
Locus ID:	27091
Synonyms:	calcium channel, voltage-dependent, gamma subunit 5; MGC126656; MGC126682; neuronal voltage-gated calcium channel gamma-5 subunit; voltage-dependent calcium channel gamma-5 subunit
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CACNG5 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>NM_014404, NM_145811, NM_145811.1, NM_145811.2, NM_014404.1, BC101607, BC101633, NM_145811.3</u>
UniProt ID:	<u>Q9UF02</u>
Summary:	The protein encoded by this gene is a type II transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members, a type I TARP and a calcium channel gamma subunit. This gene is a susceptibility locus for schizophrenia and bipolar disorder. [provided by RefSeq, Dec 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

GRIGENE CACNG5 Human shRNA Lentiviral Particle (Locus ID 27091) – TL314231V

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US